Artificial Intelligence in Head and Neck Cancer Imaging: Enhancing Detection, Prognosis, and Treatment Planning

سال انتشار: 1404
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 154

متن کامل این مقاله منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل مقاله (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

AIMS02_363

تاریخ نمایه سازی: 29 تیر 1404

چکیده مقاله:

Background and Aims: Artificial Intelligence (AI) and radiomics are revolutionizing the diagnosis, treatment, and management of head and neck cancers (HNCs). Utilizing machine learning (ML) and deep learning algorithms, AI can extract and analyze intricate radiomic features from medical imaging, enabling detailed tumor characterization and personalized treatment plans. AI-based radiomics has the potential to enhance early tumor diagnosis, predict treatment response, minimize radiation-induced side effects, and advance patient care. This study provides a comprehensive examination of AI-driven radiomics in HNC management, focusing specifically on its use in multidisciplinary tumor board decision-making. It examines the prospects, processes, and constraints of using AI in radiomics to enhance clinical decision support systems and improve cancer care. Methods: A systematic review was performed utilizing PubMed, Scopus, and Google Scholar to identify relevant studies published from ۲۰۲۰ to ۲۰۲۵. The search terms included 'AI in HNC,' 'radiomics in oncology,' 'machine learning in cancer imaging,' and 'AI-driven precision oncology.' Of the ۵۰ articles reviewed, ۲۰ were chosen based on relevance and methodological rigor. The review concentrated on the applications of AI-driven radiomics in HNC, encompassing tumor segmentation, prognostic modeling, and treatment optimization. Results: AI-driven radiomics has demonstrated considerable promise in HNC management by augmenting tumor detection precision, facilitating automated tumor segmentation, and refining predictive models for disease advancement and therapeutic response. Machine learning algorithms evaluate imaging biomarkers to inform clinical choices, thereby reducing the need for invasive treatments. The variability in data and the absence of standardization hinder the integration of AI into clinical workflows. Ethical issues must also be addressed, including patient privacy and algorithmic bias. Additionally, the absence of large-scale annotated datasets and regulatory barriers limit the widespread application of AI-driven radiomics in clinical practice. Conclusion: AI and radiomics represent significant advancements in precision medicine for managing HNCs. They offer new possibilities for improving diagnosis, treatment planning, and patient outcomes. To realize their potential, it is imperative to confront technological problems, ethical issues, and regulatory obstacles. Collaboration among researchers, doctors, and regulatory bodies will be essential for the safe and successful integration of new

نویسندگان

Sara Almasi Nezhad

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

MirAhmad Mazloomi

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Tahura Fayeghi

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Parinaz Nezhadmokhtari

Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran